{"protocolSection": {"identificationModule": {"nctId": "NCT06360354", "orgStudyIdInfo": {"id": "20230223"}, "organization": {"fullName": "Amgen", "class": "INDUSTRY"}, "briefTitle": "A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion", "officialTitle": "A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Amgen", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers."}, "conditionsModule": {"conditions": ["Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers"], "keywords": ["Advanced Cancer", "Methylthioadenosine Phosphorylase", "AMG 193", "Oncology"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 188, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Subprotocol B: Pancreatic Ductal Adenocarcinoma (PDAC) Arm A", "type": "EXPERIMENTAL", "description": "Part 1: Participants with MTAP-deleted PDAC will receive escalating doses of AMG 193 orally in combination with gemcitabine and nab-paclitaxel IV.\n\nPart 2: Participants with MTAP-deleted PDAC will receive the recommended dose of AMG 193 in combination with gemcitabine and nab-paclitaxel.", "interventionNames": ["Drug: AMG 193", "Drug: Gemcitabine", "Drug: Nab-paclitaxel"]}, {"label": "Subprotocol B: PDAC Arm B", "type": "EXPERIMENTAL", "description": "Part 1: Participants with MTAP-deleted PDAC will receive escalating doses of AMG 193 orally in combination with mFOLFIRINOX (irinotecan, fluorouracil, leucovorin calcium, oxaliplatin) IV.\n\nPart 2: Participants with MTAP-deleted PDAC will receive the recommended dose of AMG 193 in combination with mFOLFIRINOX.", "interventionNames": ["Drug: AMG 193", "Drug: Modified FOLFIRINOX"]}], "interventions": [{"type": "DRUG", "name": "AMG 193", "description": "Administered Orally", "armGroupLabels": ["Subprotocol B: PDAC Arm B", "Subprotocol B: Pancreatic Ductal Adenocarcinoma (PDAC) Arm A"]}, {"type": "DRUG", "name": "Gemcitabine", "description": "Administered IV", "armGroupLabels": ["Subprotocol B: Pancreatic Ductal Adenocarcinoma (PDAC) Arm A"]}, {"type": "DRUG", "name": "Nab-paclitaxel", "description": "Administered IV", "armGroupLabels": ["Subprotocol B: Pancreatic Ductal Adenocarcinoma (PDAC) Arm A"]}, {"type": "DRUG", "name": "Modified FOLFIRINOX", "description": "Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV", "armGroupLabels": ["Subprotocol B: PDAC Arm B"]}]}, "eligibilityModule": {"eligibilityCriteria": "Subprotocol B\n\nInclusion:\n\n* Age \u2265 18 years (or \u2265 legal age within the country if it is older than 18 years).\n* Histologically or cytologically confirmed diagnosis of metastatic and/or unresectable (locally advanced) adenocarcinoma of the pancreas.\n* Tumor tissue (FFPE sample) or an archival block must be available. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before dosing.\n* Homozygous MTAP-deletion.\n* Disease measurable as defined by RECIST v1.1.\n* Adequate organ function as defined in the protocol.\n\nExclusion:\n\n* Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor.\n* Radiation therapy within 28 days of first dose.\n* Major surgery within 28 days of first dose of AMG 193.\n* Cardiovascular and pulmonary exclusion criteria as defined in the protocol.\n* Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis).\n* History of solid organ transplantation.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "100 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Amgen Call Center", "role": "CONTACT", "phone": "866-572-6436", "email": "medinfo@amgen.com"}], "overallOfficials": [{"name": "MD", "affiliation": "Amgen", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "AmgenTrials clinical trials website", "url": "http://www.amgentrials.com"}]}}, "hasResults": false}